Full Text of HB2350 103rd General Assembly
HB2350enr 103RD GENERAL ASSEMBLY
|HB2350 Enrolled||LRB103 26427 BMS 52790 b|
AN ACT concerning regulation.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
The Illinois Insurance Code is amended by
changing Section 356u as follows:
(215 ILCS 5/356u)
Pap tests and prostate cancer screenings.
(a) A group policy of accident and health insurance that
for hospital or medical treatment or
services for illness on an
expense-incurred basis and is
amended, delivered, issued, or renewed after January 1, 2024
shall provide coverage, without imposing a deductible,
coinsurance, copayment, or any other cost-sharing requirement,
for all of
(1) An annual cervical smear or Pap smear test for
(2) An annual prostate cancer screening for
insureds upon the recommendation of a physician licensed
to practice medicine in all its branches for:
age 50 and over;
age 40 and
age 40 and over with a family
|HB2350 Enrolled||- 2 -||LRB103 26427 BMS 52790 b|
or genetic predisposition to
(3) Surveillance tests for ovarian cancer for
insureds who are at risk for ovarian cancer.
(b) This Section shall not apply to agreements, contracts,
or policies that
provide coverage for a specified disease or
other limited benefit coverage.
(c) This Section does not apply to coverage of prostate
cancer screenings to the extent such coverage would disqualify
a high-deductible health plan from eligibility for a health
savings account pursuant to Section 223 of the Internal
(d) For the purposes of this Section:
"At risk for ovarian cancer" means:
(1) having a family history (i) with one or more
first-degree relatives with ovarian cancer, (ii) of
relatives with breast cancer, or (iii)
of nonpolyposis colorectal cancer; or
(2) testing positive for BRCA1 or BRCA2 mutations.
"Prostate cancer screening" means medically viable methods
for the detection and diagnosis of prostate cancer, including
a digital rectal exam and the prostate-specific antigen test
and associated laboratory work. "Prostate cancer screening"
includes medically necessary subsequent follow-up testing as
directed by a health care provider, including, but not limited
|HB2350 Enrolled||- 3 -||LRB103 26427 BMS 52790 b|
(1) urinary analysis;
(2) serum biomarkers; and
(3) medical imaging, including, but not limited to,
magnetic resonance imaging.
"Surveillance tests for ovarian cancer" means annual
screening using (i) CA-125 serum tumor marker testing, (ii)
transvaginal ultrasound, (iii) pelvic examination.
(Source: P.A. 102-1073, eff. 1-1-23
This Act takes effect January